Substituted aminothiazoles as inhibitors of cancers, including hepatocellular carcinoma, and as inhibitors of hepatitis virus replication
Pharmaceutical compositions of the invention comprise substituted aminothiazoles derivatives having a disease-modifying action in the treatment of diseases associated with unregulated cell growth that include hepatocellular carcinoma, and infection with a hepatitis virus.
1. A compound selected from:
(4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazol-5-yl)methyl acetate;
(4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazol-5-yl)methyl butyrate;
Ethyl 4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxylate;
Tert-butyl 2-(tert-butyl(pyrimidin-2-yl)amino)-4-(pyridine-2-yl)thiazole-5-carboxylate;
Ethyl 2-((4-methylpyrimidin-2-yl)amino)-4-(pyridin-2-yl)thiazole-5-carboxylate;
4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxylic acid;
Methyl 4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxylate;
and pharmaceutically acceptable salts thereof.
2. The compound of claim 1 , wherein the compound is selected from:
Ethyl 4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxylate;
Ethyl 2-((4-methylpyrimidin-2-yl)amino)-4-(pyridin-2-yl)thiazole-5-carboxylate;
Methyl 4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxylate;
and pharmaceutically acceptable salts thereof.
3. 4-Pyridin-2-yl-2-(pyrimidin-2-ylamino)-thiazole-5-carbonitrile or a pharmaceutically acceptable salt thereof.
4. 4-Pyridin-2-yl-2-(pyrimidin-2-ylamino)-thiazole-5-carbonitrile hydrochloride.
5. A composition comprising a compound according to claim 1 , and a pharmaceutically acceptable carrier.